SAM #26-000161

NIH Sole Source Procurement: Seahorse XFe96 Analyzer Reagents and Maintenance from Agilent Technologies

This notice announces the NIH Clinical Center's intent to award a sole source contract to Agilent Technologies for Seahorse XFe96 Analyzer reagents and preventative maintenance services. - Agency: National Institutes of Health (NIH) Clinical Center, Center for Cellular Engineering - Procurement Type: Sole source, firm fixed price purchase order - Vendor: Agilent Technologies (121 Hartwell Ave, Lexington, MA 02421) - Products/Services: - Clinically approved reagents and kits for the Seahorse XFe96 Analyzer - Preventative maintenance services for the Seahorse XFe96 Analyzer - Requirements: - Maintenance must comply with manufacturer specifications and FDA 21 CFR 211.67 - Products and services are critical for patient care testing and cellular therapy product release - Justification: Agilent is the only source for these clinically approved items and services; procurement follows FAR Part 13 (Simplified Acquisition Procedures) - No specific part numbers or quantities provided - Commercial opportunity is limited to Agilent Technologies due to sole source status - Place of performance and contracting office: NIH Clinical Center, Bethesda, MD 20892

Description

This acquisition is for reagents and preventative maintenance for the Seahorse XFEe Analyzer at the National Institutes of Health (NIH) Clinical Center (CC) Center for Cellular Engineering.

•             Product Service Code: 6515 – Medical Instruments, Equipment, and Supplies

•             NAICS Code: 339112 – Surgical and Medical Instrument Manufacturing

•             Place of Performance: Bethesda, MD 20892 USA

POTS: 26-000161

Description:

This is a notice of intent, not a request for a quotation.  A solicitation document will not be issued and quotations will not be requested.

The National Institutes of Health (NIH) intends to award a fixed price purchase order to Agilent Technologies, located at 121 Hartwell Ave, Lexington, MA 02421, on a firm fixed price sole source award basis to provide reagents and preventative maintenance services to the National Institutes of Health.

The proposed vendor, Agilent technologies, provides the clinically approved platform for reagents, kits, and the respective instruments that may be used for patient care testing on clinical and research cellular products. Preventive maintenance is required to compliance with the manufacturer and FDA 21 CFR 211.67. The Seahorse XFe96 is a unique instrument that can help us measure cellular potency using metabolic activity following CAR T cell and other cell product of manufacturing. This instrument is needed to generate data that is required for the release of the cellular therapy product. Agilent technologies is the sole vendor that provides the periodic Preventive Maintenance (PM) for this type of device.

This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available.  Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.

Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government.

Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Kristin Nagashima, Contract Specialist via email to Kristin.nagashima@nih.gov by May 4, 2026 at 2pm EST.

View original listing